Cardiac biomarkers are protein-based
observable substances used as an indicator of biologic state, also called
cardiac markers. These biomarkers are released into the bloodstream when heart
is stressed, or its muscles are damaged. They includes different type of
hormones, enzymes, and proteins, for instance cardiac troponins,
ischemia-modified albumin (IMA), creatine kinase (CK), and myoglobin. These are
used as risk stratification for many cardiovascular diseases (CVDs), which
include congestive heart failure, myocardial infraction, acute coronary
syndrome (ACS) among others.
The key features are included quick outcomes,
cost effective, high accuracy, non-invasive and economic pricing of cardiac
point of care (POC) testing.
According to study, “Global
Cardiac Biomarkers Market Size study, by type (Myocardial muscle Creatine
Kinase, Myoglobin, Troponins (T and I), Ischemia Modified Albumin (IMA), Brain
Natriuretic Peptide (BNPs) or NT-proBNP and Others) Application (myocardial
infarction, congestive heart failure, acute coronary syndrome, Atherosclerosis,
other applications) Location of Testing (point of care testing and laboratory
testing) and Regional Forecasts 2018-2025.” the key companies operating
in the global cardiac biomarkers market are Roche Diagnostics Corp., Siemens
Healthcare GmbH, Abbott Laboratories Inc., Alere Inc., F. Hoffmann-La Roche
Ltd., Tosoh Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Becton
Dickinson and Company, Randox laboratories, Johnson and Johnson, BioMerieux SA,
Thermo Fisher Scientific Inc., Olympus Corporation, Beckman Coulter Inc., BG
Medicines, Boditech Med Inc., Ortho-Clinical Diagnostics, Inc., Quidel Corporation,
Response Biomedical Corp., BG Medicine, Inc., Trivitron Healthcare, Trinity
Biotech. The key companies are focusing on innovative technologies for instance
automated, multi-assay by combinations of cardiac biomarkers &
point-of-care (PoC) cardiac biomarker devices.
Based on type, cardiac biomarkers market is
segmented into myocardial muscle Creatine Kinase (CK-MB), Myoglobin, Troponins
(T and I), Natriuretic peptides - B-type Natriuretic Peptide (BNP) &
N-terminal pro b-type Natriuretic peptide (NT-proBNP), LDH isoenzymes,
Heart-type Fatty Acid Binding Protein (H-FABP), and Ischemia Modified Albumin
(IMA). Troponins T and I holds major share in market owing to its prodigious
specificity and ability to accurately identify the cardiac events of Acute Coronary
Syndrome (ACS). Based on application, market is segmented into myocardial
infarction, acute coronary syndrome, cardiomyopathy, myocarditis, ischemia,
congestive heart failure and atrial fibrillation. Based on location of testing,
market is segmented into point of care testing and laboratory testing. In
addition, based on end-user, market is segmented into hospitals & clinics
and diagnostics laboratories.
The cardiac biomarkers market is driven by
increase in prevalence of cardiovascular diseases, followed by rise in point of
care (POC) testing, increase in funding from public & private organizations
for research & development (R&D), rise in awareness towards cardiac
diagnostics solutions, high demand for cardiac testing, growth in patient
population and technological advancements using cardiac biomarkers
combinations. However, poor reimbursement policies and stringent regulation may
impact the market. Moreover, personalized medicine, future developments in
novel cardiac biomarkers and POC testing using cardiac biomarkers are key
opportunities for market.
Based on geography, the North-American region
holds major share, followed by European region in cardiac biomarkers market
owing to lack of physical activity & unhealthy diet and high cardiovascular
diseases prevalence rate in the region. The Asian-Pacific region is expected to
witness higher growth rate due to modernization, increase in affordability for
advanced cardiac treatments and rise in disposable incomes over the forecast
period.
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91
9015378249
No comments:
Post a Comment